Shares of Gilead Sciences Inc. GILD inched 0.06% higher to $83.99 Monday, on what proved to be an all-around great trading ...

The manufacturer says the drug is indicated for the treatment of Covid-19 in adults and children, but an unexpected presence ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Shanghai-based Fosun Pharmaceutical has acquired the remaining 50% stake in Fosun Kite Biotechnology from Kite Pharma for $27 ...

With rapid innovations in biotechnology, companies are developing groundbreaking therapies and diagnostic tools that address ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta achieved sales exceeding USD 1.5 billion, ...

Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory diseases. The agreement ...

Public health groups raise concern on patent grant to promising, new HIV drug Patient and public health groups have raised concerns over a potential patent grant to Gilead Sciences for the HIV drug ...

The South San Francisco company has enticed Gilead with its vision of using AI and machine learning to transform drug discovery, getting $15 million in upfront backing in a deal that could be ...